Segment and Other Information

9 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Segment and Other Information

Segment and Other Information

Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment, which is the development and commercialization of meaningful pharmaceutical products that address unmet medical needs. The following table presents a summary of total revenues (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Xyrem® (sodium oxybate) oral solution	$	242,899	$	204,337	$	703,435	$	556,081
Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi)	56,317		52,121		152,821		146,910
Defitelio® (defibrotide)/defibrotide	19,639		18,892		52,259		51,345
Prialt® (ziconotide) intrathecal infusion	6,042		6,282		19,944		16,422
Psychiatry	9,910		10,833		28,375		32,431
Other	3,947		11,942		21,061		35,304
Product sales, net	338,754		304,407		977,895		838,493
Royalties and contract revenues	2,118		2,177		6,027		6,240
Total revenues	$	340,872	$	306,584	$	983,922	$	844,733

The following table presents a summary of total revenues attributed to geographic sources (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
United States	$	305,585	$	264,719	$	877,397	$	727,200
Europe	26,076		32,578		82,837		87,608
All other	9,211		9,287		23,688		29,925
Total revenues	$	340,872	$	306,584	$	983,922	$	844,733

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Express Scripts	71	%	67	%	71	%	66	%
McKesson	14	%	1	%	5	%	5	%
Accredo Health Group, Inc.	—	%	14	%	8	%	14	%

At the end of the second quarter of 2015, we transitioned the U.S. distribution of Erwinaze from Accredo Health Group, Inc. to McKesson.

The following table presents total long-lived assets, consisting of property and equipment, by location (in thousands):

	September 30, 2015		December 31, 2014
Ireland	$	60,447	$	37,775
United States	12,255		9,795
Italy	8,424		8,462
Other	2,326		2,331
Total long-lived assets	$	83,452	$	58,363